MGMT and hepatocellular carcinoma: Patients with advanced hepatocellular carcinoma have been treated with temozolomide plus a MAPK/ERK inhibitor (U0126) because this combination increases the susceptibility of HCC cells to TMZ and down-regulates MGMT expression by blocking the MAPK/ERK signaling pathway 138.